News

Key is to recognize usual patterns for systemic and topical medications

Transient sensory-motor abnormalities are often common

Injections and implants continue to create further positive outcomes for patients.

Novel option demonstrates stable to improved visual acuity and retinal thickness

Minimizing clinic visits, maximizing use of imaging modalities are key

Options for physicians are increasing in availability, with fewer costs and travel burdens for patients

Ophthalmologist provides patient counseling pearls for selected retinal dystrophies

Novel gene therapy/medical device combo sheds light on retina in RP

Study highlights role of demographic and socioeconomic characteristics in treatment

Rapid fluid identification may result in better visual outcomes

Specialist explains approaches for a variety of cases encountered during procedure

According to investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells, by removing a membrane that lines the back of the eye they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Annual Bascom Palmer Eye Institute program will spotlight latest advances in neovascular and exudative ocular disease over 2-day event, February 12-13.

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.

The FDA has granted Fast Track designation to MeiraGTx's AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM).

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

According to an abstract presented during the 2020 Virtual Retina Society Annual Meeting, women are 34% less likely to receive a repair for a retinal detachment compared with men.

Thanks to researchers like Russell N. Van Gelder, MD, PhD, the possibility of restoring sight to people blinded by age-related macular degeneration or retinitis pigmentosa is another step closer to reality.

Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.

During AAO 2020, Neal H. Shorstein, MD, explains how physicians at Kaiser Permanente have a streamlined regimen using a prophylactic drop-free drug before cataract surgery for more than a decade.

Rudy Nuijts of the University Eye Clinic Maastricht, the Netherlands, discusses the highlights of his AAO 2020 presentation on a combination treatment regimen for lowering the incidence of cystoid macular oedema following category surgery.

Kristen Brotherson, vice president, US surgical marketing for Alcon, discusses some of the recent advances in cataract surgery-related technologies, including a new advanced lens for patients with presbyopia (AcrySof IQ Vivity IOL).

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

During AAO 2020, Kathleeen B. Digre, MD, details how a headache in conjunction with visual loss is a scenario that requires an in-depth examination, including evaluation of the visual fields, pupils, and fundus to gather clues to the diagnosis.

Tamer Mahmoud, MD, PhD, discusses autologous retinal transplant (ART) for macular holes, a procedure he developed, which is providing anatomic hole closure in the vast majority of cases as well as increases in visual acuity.

In a presentation at the American Academy of Ophthalmology’s virtual 2020 annual meeting, Amy K. Hutchinson, MD, explained that while Myopia has been occurring at epidemic rates worldwide, research has found that the use of orthokeratology and multifocal contact lenses can provide clinically meaningful reductions in myopia progression.

Ram Liebenthal, U.S. general manager for Heidelberg Engineering, discusses how the company continues to invest in the Spectralis platform in terms of hardware and software improvements.